Alloy and Pyxis spin out new ‘company’ around high-risk I/O, immunology targets
Alloy and Pyxis spin out new ‘company’ around high-risk I/O, immunology targets Read More »
May 25, 2021
Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
LEXINGTON & CAMBRIDGE, Mass., May 25, 2021 – Alloy Therapeutics (“Alloy”) and Pyxis Oncology (“Pyxis”) today announced the formation of a joint venture named Kyma Therapeutics to develop immune-modulating antibodies for novel targets in cancer and autoimmune diseases. Kyma Therapeutics will advance programs directed to immune-modulating targets identified by Pyxis. Alloy Discovery Services will generate
